Zydus Taps Into Blockbuster Cancer Drug Market with Tentative USFDA Green Light

Unknown Apr 02, 2026 1,150 Views

Zydus Lifesciences Ltd has received tentative approval from the U.S. Food and Drug Administration (USFDA) to market Ibrutinib Tablets in strengths of 140 mg, 280 mg, and 420 mg. The drug is a kinase inhibitor used in the treatment of several types of blood cancers, including chronic lymphocytic l...